Ciclosporin — Drug Intelligence | 24 EU Trials

Filter these 24 trials by condition, phase, country and more.

Open in Search →

24 Registered trials

13 Recruiting

5 Completed trials

22 Sponsors

19 Countries

Phase III

Phase II

Phase IV

Phase III: 6 Phase II/III: 2 Phase II: 8 Phase IV: 8

Oversight events:

1 urgent safety measure 1 unexpected event 1 corrective measure across 2 trials

View oversight register →

Indications tested

Autoinflammation with infantile enterocolitis 1 Myelodysplastic syndrome 1 Myasthenia gravis 1 Immune-mediated enterocolitis 1 Vernal keratoconjunctivitis 1 Immune thrombocytopenia 1 Renal transplant 1

Sponsors using this IMP

Assistance Publique Hopitaux De Paris 2 Centre Hospitalier Universitaire De Nantes 2 Universitair Medisch Centrum Groningen 2 Argenx 1 Azienda Sanitaria Universitaria Friuli Centrale 1 Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia 1 Bristol-Myers Squibb Services Unlimited Company 1 Centre Hospitalier Universitaire Rouen 1 Fakultni Nemocnice Hradec Kralove 1 Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz 1 Hospital Clinico San Carlos 1 Kyverna Therapeutics Inc. 1

All trials

24 total

AliCsa; Efficacy of oral alitretinoin versus oral cyclosporine in patients with moderate to very severe hand eczema. A randomized prospecti… Pending

2024-515140-23-00 Phase IV 1 country Universitair Medisch Centrum Groningen
Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAemia after kidney… Pending

2024-517219-56-00 Phase IV 1 country Paediatrisches Forschungsnetzwerk gGmbH; PROFIL Institut fuer Stoffwechselforsch…
Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell … Pending

2024-520326-11-00 Phase II 1 country Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
A Study to Compare the Effectiveness and Safety of T1695 (0.1% Tacrolimus) Versus Ciclosporin in Participants With Moderate to Severe Vernal… Pending

2025-521567-12-00 Phase II 5 countries Laboratoires Thea
Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a rand… Pending

2025-523551-54-00 Phase IV 1 country Azienda Sanitaria Universitaria Friuli Centrale
ALTERNATION Trial: A Clinical Trial Evaluating Everolimus-Based, Calcineurin Inhibitor-Free Immunosuppression One Year After Liver Transplan… Pending

2025-524312-11-00 Phase III 1 country Medizinische Hochschule Hannover
Interest of belatacept as a non-nephrotoxic immunosuppressive treatment in cardiac transplant patients at risk of chronic renal failure. Recruiting

2024-516541-40-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and the… Recruiting

2022-501677-39-00 Phase III 6 countries Bristol-Myers Squibb Services Unlimited Company
Immunosuppression regimen reduction in kidney transplantation recipients admitted to the intensive care unit in the setting of septic shock … Recruiting

2024-518493-14-00 Phase II/III 1 country Les Hopitaux Universitaires De Strasbourg
Comparison of the effects of Belatacept and Anticalcineurins on endothelial function in kidney transplant patients - BELAFENDO Recruiting

2024-515577-10-00 Phase IV 1 country Centre Hospitalier Universitaire Rouen
Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM) Recruiting

2023-505788-35-00 Phase II 1 country Fakultni Nemocnice Hradec Kralove
Ikervis in the Treatment of Atopic Keratoconjunctivitis - a Prospective, Randomized, Placebo-Controlled Trial Recruiting

2022-500633-92-00 Phase II 1 country Rigshospitalet
A phase II, multicenter, 1:1 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of bolus applicatio… Recruiting

2024-511037-35-00 Phase II 1 country Universitaetsklinikum Heidelberg AöR
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Generalized Myasthenia Gravis Recruiting

2023-509892-17-00 Phase II/III 1 country Kyverna Therapeutics Inc.
A multi-centre, open, prospective, randomized, parallel-group, 24-month study to compare the outcome of receiving continued immunosuppressio… Recruiting

2023-506879-98-00 Phase IV 1 country Vall D'hebron Institut De Recerca
Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid l… Recruiting

2023-504555-27-00 Phase III 1 country Assistance Publique Hopitaux De Paris
A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting

2022-502851-79-00 Phase III 19 countries Argenx
FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busul… Recruiting

2022-502019-12-00 Phase III 1 country Centre Hospitalier Universitaire De Nantes
DFIL2-REP - Study of the clinical and biological response to repeated administration of low-dose interleukin-2 in patients with type 1 diabe… Recruiting

2024-514043-29-00 Phase II 1 country Assistance Publique Hopitaux De Paris
Optimization of Cyclosporin therapy in atopic dermatitis through multiomic predictive models of treatment response (DermAtOmics) Ended

2022-500677-14-00 Phase IV 1 country Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz
Study to evaluate the efficacy and safety of MAS825 in patients with autoinflammatory diseases. Ended

2023-504419-34-00 Phase II 4 countries Novartis Pharma AG
A clinical trial evaluating the efficacy and safety of the drugs - cyclosporine and methotrexate in children and adolescents with moderate t… Ended

2023-509759-15-00 Phase III 1 country Medical University Of Lodz
Clinical Trial To Determine The Effectiveness And Safety Of Topical Insulin In Dry Eye Ended

2024-518376-31-00 Phase IV 1 country Hospital Clinico San Carlos
OPTIMIZE Ended

2024-516509-22-00 Phase IV 2 countries Universitair Medisch Centrum Groningen

Showing 1–24 of 24 trials

← All drugs A–Z